BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BDS, Scolapio JS, Malespin M, de Melo Jr SW. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report. World J Gastrointest Pharmacol Ther 2019; 10(1): 29-34 [PMID: 30697447 DOI: 10.4292/wjgpt.v10.i1.29]
URL: https://www.wjgnet.com/2150-5349/full/v10/i1/29.htm
Number Citing Articles
1
Alan Su, Rodrigo Pedraza, Hagen Kennecke. Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal CancerCurrent Oncology 2023; 30(4): 3672 doi: 10.3390/curroncol30040279
2
David Anson, Joseph Norton, Benjamin Chaucer, Saurabh Bansal. Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc ProlongationCase Reports in Oncological Medicine 2019; 2019: 1 doi: 10.1155/2019/7896749
3
Preeya Goyal, Justin T. Moyers, Bassem G. Elgohary, Muhammad B. Hammami. Case Report: Nivolumab-Induced Autoimmune PancreatitisJournal of Immunotherapy and Precision Oncology 2021; 4(4): 208 doi: 10.36401/JIPO-21-11
4
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCUGastroenterología y Hepatología (English Edition) 2024; 47(4): 401 doi: 10.1016/j.gastre.2023.10.003
5
Neeta Malviya, Ian W. Tattersall, Jonathan Leventhal, Allireza Alloo. Cutaneous immune-related adverse events to checkpoint inhibitorsClinics in Dermatology 2020; 38(6): 660 doi: 10.1016/j.clindermatol.2020.06.011
6
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCUGastroenterología y Hepatología 2024; 47(4): 401 doi: 10.1016/j.gastrohep.2023.10.009
7
Carolina Lopes, Sandra Morgado, Ana I. Plácido, Fátima Roque, Manuel Morgado. Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity ManagementSN Comprehensive Clinical Medicine 2021; 3(1): 84 doi: 10.1007/s42399-020-00670-w
8
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCURevista Española de Enfermedades Digestivas 2024;  doi: 10.17235/reed.2024.10250/2024
9
Manuel Morgado, Ana Plácido, Sandra Morgado, Fátima Roque. Management of the Adverse Effects of Immune Checkpoint InhibitorsVaccines 2020; 8(4): 575 doi: 10.3390/vaccines8040575
10
Eveline Daetwyler, Till Wallrabenstein, David König, Laura C Cappelli, Jarushka Naidoo, Alfred Zippelius, Heinz Läubli. Corticosteroid-resistant immune-related adverse events: a systematic reviewJournal for ImmunoTherapy of Cancer 2024; 12(1): e007409 doi: 10.1136/jitc-2023-007409